Search Results - "Segura Díaz, Adrián"

Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms by Stuckey, Ruth, Bilbao-Sieyro, Cristina, Segura-Díaz, Adrián, Gómez-Casares, María Teresa

“…V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). mutations are also frequent in clonal…”
Get full text

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors by Pérez-Lamas, Lucía, Luna, Alejandro, Boque, Concepción, Xicoy, Blanca, Giraldo, Pilar, Pérez López, Raúl, Ruiz Nuño, Concepción, De Las Heras, Natalia, Mora Casterá, Elvira, López Marín, Javier, Segura Díaz, Adrián, Gómez, Valle, Vélez Tenza, Patricia, Sierra Pacho, Magdalena, Vera Goñi, Juan Antonio, Moreno Vega, Melania, Alvarez-Larrán, Alberto, Cortés, Montse, Pérez Encinas, Manuel, Carrascosa Mastell, Patricia, Angona, Anna, Rosell, Ana, Lakhwani, Sunil, Colorado, Mercedes, Ramila, Elena, Cervero, Carlos, Cuevas, Beatriz, Villalón Blanco, Lucía, de Paz, Raquel, Paz Coll, Antonio, Fernández, María José, Felipe Casado, Luis, Alonso-Domínguez, Juan Manuel, Anguita Arance, María Magdalena, Salamanca Cuenca, Araceli, Jiménez-Velasco, Antonio, Prendes, Santiago Osorio, Santaliestra, Marta, Lis Chulvi, María José, Hernández-Boluda, Juan Carlos, García-Gutiérrez, Valentín

“…(1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients…”
Get full text

Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib by Pérez-Lamas, Lucía, Díaz, Adrián Segura, Casterá, Elvira Mora, Soto, Marta Hidalgo, Coll, Antonio Paz, De las Heras, Natalia, Cortes, Montse, Tenza, Patricia Vélez, Pacho, Magdalena Sierra, Magan, Alicia Senin, Angona, Anna, Cervero, Carlos, de Paz, Raquel, Cuenca, Araceli Salamanca, Santaliestra, Marta, Marín, Javier López, Casado, Luis Felipe, García-Gutiérrez, Valentín

“…Patients with chronic myeloid leukemia (CML) who have failed conventional tyrosine kinase inhibitors (cTKIs) and asciminib constitute a complex group of…”
Get full text

Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment by Stuckey, Ruth, Segura-Díaz, Adrián, Sáez Perdomo, María Nieves, Pérez Encinas, Manuel Mateo, González San Miguel, Jóse David, Florido, Yanira, Sánchez-Sosa, Santiago, López-Rodríguez, Juan Francisco, Bilbao-Sieyro, Cristina, Gómez-Casares, María Teresa

“…For chronic myeloid leukemia (CML) patients with a known risk of cardiovascular events (CVE), imatinib is often recommended for first-line tyrosine kinase…”
Get full text

Quantification of JAK2 V167F in Patients with Myeloproliferative Neoplasms: Comparison of NGS and Digital PCR with Quantitative PCR by Stuckey, Ruth, Santana, Guillermo, Florido, Yanira, Segura-Díaz, Adrián, Gómez-Casares, Maria Teresa, Bilbao-Sieyro, Cristina

“…Introduction: JAK2 V617F is the most common mutation in the Philadelphia-negative myeloproliferative neoplasms (MPN), detected in 97% of polycythemia vera…”
Get full text

Biological Factors Associated with Treatment-Free Remission in Clinical Practice: Data from the Canarian Registry of CML by Stuckey, Ruth, Sánchez-Sosa, Santiago, Estupiñan Cabrera, Paula, Cruz Rodríguez, Cristian, Segura-Díaz, Adrián, Lakhwani, Sunil, González San Miguel, José David, Hernanz Soler, Nuria, Gordillo, Marina, González Brito, Gloria, Tapia Torres, Maria, Bilbao-Sieyro, Cristina, Gómez-Casares, Maria Teresa

“…Introduction: The probability of maintaining treatment-free remission (TFR) after the discontinuation of tyrosine kinase inhibitors (TKI) is affected by…”
Get full text

The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia by Saez Perdomo, María Nieves, Stuckey, Ruth, González-Pérez, Elena, Sánchez-Sosa, Santiago, Estupiñan-Cabrera, Paula, Lakhwani Lakhwani, Sunil, González San Miguel, José David, Hernanz Soler, Nuria, Gordillo, Marina, González Brito, Gloria, Tapia-Torres, María, Ruano, Ana, Segura-Díaz, Adrián, Luzardo, Hugo, Bilbao-Sieyro, Cristina, Gómez-Casares, María Teresa

“…Second- and third-generation tyrosine kinase inhibitors (TKIs) are now available to treat chronic-phase chronic myeloid leukemia (CP-CML) in the first and…”
Get full text

DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study by Segura-Díaz, Adrián, Stuckey, Ruth, Florido, Yanira, Sobas, Marta, Álvarez-Larrán, Alberto, Ferrer-Marín, Francisca, Pérez-Encinas, Manuel, Carreño-Tarragona, Gonzalo, Fox, María L, Tazón Vega, Barbara, Cuevas, Beatriz, López Rodríguez, Juan F, Sánchez-Farías, Nuria, González-Martín, Jesús M, Gómez-Casares, María T, Bilbao-Sieyro, Cristina

“…Polycythemia vera (PV) patients are classified as high or low thrombotic risk based on age and prior history of thrombosis. Despite adherence to treatment…”
Get more information

Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations by Segura-Díaz, Adrián, Stuckey, Ruth, Florido, Yanira, González-Martín, Jesús María, López-Rodríguez, Juan Francisco, Sánchez-Sosa, Santiago, González-Pérez, Elena, Sáez Perdomo, María Nieves, Perera, María Del Mar, de la Iglesia, Silvia, Molero-Labarta, Teresa, Gómez-Casares, María Teresa, Bilbao-Sieyro, Cristina

“…The development of thrombotic events is common among patients with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). We…”
Get full text

Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia by Stuckey, Ruth, López-Rodríguez, Juan Francisco, Sánchez-Sosa, Santiago, Segura-Díaz, Adrián, Sánchez-Farías, Nuria, Bilbao-Sieyro, Cristina, Gómez-Casares, María Teresa

“…Clinical trials have demonstrated that some patients with chronic myeloid leukemia (CML) treated for several years with tyrosine kinase inhibitors (TKIs) who…”
Get full text

Outcomes of Chronic Myeloid Leukemia Patients after Therapeutic Failure to Asciminib, a Multicenter Observational Study by Pérez-Lamas, Lucía, Segura Diaz, Adrian, Mora, Elvira, Hidalgo Soto, Marta, Paz Coll, Antonio, De Las Heras, Natalia, Cortes, Montse, Velez Tenza, Patricia, Sierra Pacho, Magdalena, Senin, María Alicia, Angona, Anna, Cervero, Carlos, De Paz Arias, Raquel, Salamanca Cuenca, Araceli, Santaliestra, Marta, López Marin, Javier, Casado Montero, Luis Felipe, García Gutiérrez, Valentín

“…Introduction: Asciminib has recently entered the market as a promising option for patients with chronic myeloid leukemia (CML) and therapeutic failure to ³ 2…”
Get full text

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors by Pérez-Lamas, Lucía, Luna, Alejandro, Boque, Concepcion, Senin, María Alicia, Xicoy, Blanca, Giraldo, Pilar, Perez Lopez, Raul, Ruiz Nuño, Concepción, De las Heras, Natalia, Mora Casterá, Elvira, Garcia-Hernandez, Carmen, Segura Diaz, Adrian, Steegmann, Juan Luis, Velez Tenza, Patricia, Sanchez-Guijo, Fermin, Garcia-Noblejas Moya, Ana Maria, Juan Vera Goñi, Juan Antonio, Moreno Vega, Melania, Alvarez-Larran, Alberto, Cortes, Montse, Perez Encinas, Manuel, Serrano, Luis, Angona, Anna, Rosell, Ana, Lakhwani, Sunil, Colorado, Mercedes, Ramila, Elena, Cervero, Carlos, Cuevas, Beatriz, Villalon Blanco, Lucia, Hernandez Boluda, Juan Carlos, Paz Coll, Antonio, Gómez García de Soria, Valle, Fernández, Maria Jose, Casado, Luis Felipe, Alonso-Dominguez, Juan Manuel, Anguita Arance, Maria Magdalena, Carrascosa Mastell, Patricia, Salamanca Cuenca, Araceli, Jiménez-Velasco, Antonio, Ramírez, María José, López Esteban, Miguel, Sierra Pacho, Magdalena, Santaliestra, Marta, Alda Alvarez, Olga, de Paz, Raquel, García Gutiérrez, Valentín

Get full text